Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2,29

 

EUR

 

-2,55 %

Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

4.759 investorer følger denne virksomhed
Sammenligne
-2,55%
+1,33%
+0,44%
+13,37%
+21,49%
+21,49%
+24,8%
-32,45%
-55,96%

Biohit is a medical technology company. The company develops and manufactures laboratory equipment, supplies, and diagnostic analysis systems adapted for research, care, and industrial laboratories. In addition to the main activities, technical support, maintenance, and training services are offered within the mentioned work area. The largest presence is in the Nordic market. The company is headquartered in Helsinki.

Læs mere
Markedsværdi
34,77 mio. EUR
Aktieomsætning
36,54 t EUR
P/E (adj.) (24e)
14,84
EV/EBIT (adj.) (24e)
11,17
P/B (24e)
2,9
EV/S (24e)
1,9
Udbytteafkast, % (24e)
-
Coverage
Anbefaling
Køb
Kursmål
2.90 EUR
Opdateret
23.12.2024
Disclaimer
Latest research

Latest analysis report

Released: 23.12.2024

Latest extensive report

Released: 02.07.2023

Finanskalender
12.2
2025

Årsrapport '24

4.6
2025

Generalforsamling '24

6.8
2025

Delårsrapport Q2'25

Risiko
Business risk
Valuation risk
Lav
Høj
ViserAlle indholdstyper

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Analytikerkommentar af
Antti Siltanen

Biohit is working on a new market launch and FDA approval

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3, but the company reports on its progress on the IR blog. The Q3 blog did not comment on progress against financial targets this time, so we expect the business to have continued to operate within the guidance range of 15-20% growth.

Biohit
Biohit H1'24 preview: Opening of a new strategy period
Analytikerkommentar af
Antti Siltanen

Biohit H1'24 preview: Opening of a new strategy period

Biohit will release its H1 report on Wednesday, August 7 at 9:30 am EEST. We expect the company to continue healthy growth during the first six months of the new strategy period. We expect the result to be at the level of the comparison period, as growth investments increase costs.

Biohit
Analytikerkommentar af
Antti Siltanen

Biohit strengthens R&D

On Friday, Biohit announced that it will change its organization to strengthen the company’s strategic and operational performance of R&D.

Biohit
Analytikerkommentar af
Antti Siltanen

Biohit's Q1 has gone according to plan

Biohit that reports semi-annually does not publish business reviews for Q1 and Q3 but the company reports on its progress in the CEO’s blog. According to the blog, the implementation of the new strategy 2024-2028 started in Q1 as planned and on schedule.

Biohit
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.